Table 3

 Additional scenarios of full compliance with 40 mg simvastatin daily within the population of the heart protection study. Values are life years gained unless stated otherwise

Treatment Five year risk of major vascular event at start of treatment
12% 18% 22% 28% 42%
Lifetime use of generic simvastatin*
Age at start (years):
 40-49 0.47 0.63 0.72 0.84 0.97
 50-59 0.43 0.54 0.63 0.72 0.83
 60-69 0.36 0.43 0.50 0.56 0.66
 ≥70 0.27 0.33 0.37 0.43 0.51
5 year use of generic simvastatin
Age at start (years):
 40-49 0.09 0.13 0.17 0.21 0.29
 50-59 0.11 0.15 0.19 0.23 0.32
 60-69 0.13 0.17 0.20 0.25 0.35
 ≥70 0.14 0.17 0.20 0.24 0.34
Lifetime use of proprietary simvastatin
Age at start (years):
 40-49 0.62 0.81 0.94 1.08 1.24
 50-59 0.58 0.71 0.82 0.94 1.08
 60-69 0.50 0.58 0.66 0.75 0.88
 ≥70 0.38 0.45 0.50 0.57 0.68

*Values are quality adjusted life years gained (adjusted for age specific and sex specific health related quality of life).

All results discounted at 3.5% per annum.